Prognostic significance of extracapsular extension in patients with non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a retrospective cohort study - Scorecard - MDSpire
Advertisement
Prognostic significance of extracapsular extension in patients with non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a retrospective cohort study
Clinical Scorecard: Impact of Extracapsular Extension on Survival Outcomes in Non-Small Cell Lung Cancer Patients After Neoadjuvant Chemoimmunotherapy: A Retrospective Analysis
At a Glance
Category
Detail
Condition
Non-small cell lung cancer (NSCLC)
Key Mechanisms
Extracapsular extension (ECE) as a hallmark of aggressive tumor biology and its impact on disease-free survival (DFS)
Target Population
Patients with NSCLC and pathologically confirmed lymph node metastasis undergoing neoadjuvant chemoimmunotherapy
Care Setting
Oncology surgical care following neoadjuvant treatment
Key Highlights
ECE-positive patients had significantly worse DFS compared to ECE-negative patients.
ECE is an independent prognostic factor for DFS (HR = 2.37, P = 0.006).
Integrating ECE status with major pathologic response improved predictive accuracy for 2-year DFS.
Lymphovascular invasion (LVI) is an independent predictor of overall survival (OS).
Intensified postoperative surveillance is warranted for patients with ECE.
Guideline-Based Recommendations
Diagnosis
Pathological assessment of ECE should be performed to evaluate tumor aggressiveness.
Management
Consider intensified postoperative surveillance for patients with ECE.
Monitoring & Follow-up
Monitor for disease recurrence in patients with ECE following neoadjuvant treatment.
Risks
Patients with ECE are at higher risk for disease recurrence.
Patient & Prescribing Data
Patients with NSCLC treated with neoadjuvant chemoimmunotherapy and subsequent surgical resection.
Neoadjuvant chemoimmunotherapy improves pathologic response but does not eliminate recurrence risk.
Clinical Best Practices
Utilize ECE status in risk stratification for NSCLC patients post-NCIT.
Implement regular follow-up protocols for early detection of recurrence in high-risk patients.
